Document is current

Article History

Received: 4 November 2024

Accepted: 12 December 2024

First Online: 7 January 2025

Declarations

:

: The authors declare the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Samah Hayek, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, Ran D. Balicer, Doron Netzer, and Alon Peretz are employees of Clalit Health Services. Clalit Research Institute received funding from AstraZeneca to support the execution of this study. Joseph Levy and Galit Shaham were employees of Clalit Health Services at the time of this study. Dr Levy’s current affiliation is the Hebrew University of Jerusalem. Dr Shaham’s current affiliation is J2 Health. Sabada Dube, Cátia Ferreira, Idit Livnat, Carla Talarico, Sylvia Taylor, Sudhir Venkatesan, and Adva Yarden are employees of, and may hold stock and/or stock options in, AstraZeneca. The AstraZeneca team was blinded to the raw data and results during the data extraction and analysis phases and only had access to aggregated data as a Word document. Data extraction, analysis, and interpretation were conducted independently by the Clalit Health Services team, and discussions between both teams took place during the protocol development and manuscript preparation phases to ensure transparency and scientific rigor.

: This study used de-identified patient data and was approved by the Clalit Health Services institutional review board.